We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $20B
1-Year Est. Return 154.41%
This Fund
S&P 500
This Quarter Est. Return
+2.27%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$17.4B
AUM Growth
+$337M
Cap. Flow
+$511M
Cap. Flow %
2.93%
Top 10 Hldgs %
73.49%
Holding
93
New
8
Increased
18
Reduced
6
Closed
9

Top Buys

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$194M
2
GRAL
GRAIL Inc
GRAL
+$151M
3
INSM icon
Insmed
INSM
+$127M
4
MIRM icon
Mirum Pharmaceuticals
MIRM
+$42M
5
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$31.4M

Top Sells

Rank Stock Value
1
RARE icon
Ultragenyx Pharmaceutical
RARE
+$63.8M
2
IMCR icon
Immunocore
IMCR
+$51.4M
3
TERN
Terns Pharmaceuticals
TERN
+$38.4M
4
BNTX icon
BioNTech
BNTX
+$25.6M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$22M

Sector Composition

Rank Sector Weight
1 Healthcare 99.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LBRX
76
LB Pharmaceuticals
LBRX
$1.54B
$4.93M 0.03%
200,000
– –
VSTM icon
77
Verastem
VSTM
$596M
$3.1M 0.02%
+584,757
New +$3.61M
TCRX icon
78
TScan Therapeutics
TCRX
$52.8M
$2.81M 0.02%
2,784,792
– –
SKYE icon
79
Skye Bioscience
SKYE
$17.6M
$968K 0.01%
1,575,243
+124,605
+9% +$102K
SANA icon
80
Sana Biotechnology
SANA
$1.06B
$894K 0.01%
310,483
– –
ALGS icon
81
Aligos Therapeutics
ALGS
$43M
$617K ﹤0.01%
83,055
– –
TYRA icon
82
Tyra Biosciences
TYRA
$1.51B
$406K ﹤0.01%
10,607
– –
SRZNW
83
DELISTED
Surrozen Inc Warrant
SRZNW
$13.3K ﹤0.01%
833,333
– –
ACRV icon
84
Acrivon Therapeutics
ACRV
$83.5M
– –
-22,809
Closed -$55K
BCRX icon
85
BioCryst Pharmaceuticals
BCRX
$2.49B
– –
-2,822,727
Closed -$22M
FDMT icon
86
4D Molecular Therapeutics
FDMT
$637M
– –
-475,737
Closed -$3.57M
KALA icon
87
KALA BIO
KALA
$18.3M
– –
-36,081
Closed -$1M
NUVL
88
DELISTED
Nuvalent
NUVL
– –
-143,937
Closed -$14.5M
RARE icon
89
Ultragenyx Pharmaceutical
RARE
$2.61B
– –
-2,772,692
Closed -$63.8M
TERN
90
DELISTED
Terns Pharmaceuticals
TERN
– –
-950,000
Closed -$38.4M
VIR icon
91
Vir Biotechnology
VIR
$1.56B
– –
-542,539
Closed -$3.27M
VTYX
92
DELISTED
Ventyx Biosciences
VTYX
– –
-2,349,280
Closed -$21.2M
1 2 3
4

Similar funds

FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
SA
Situational Awareness San Francisco, California $20.2B AUM 612.59% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

Baker Bros. Advisors's Q1 2026 Portfolio in Review

As of Q1 2026, Baker Bros. Advisors held 93 positions worth $17.4B, up 2% from $17.1B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Baker Bros. Advisors's Q1 2026 filing shows 8 new, 18 increased, 6 reduced and 9 closed positions. Its largest new stake was Mirum Pharmaceuticals: 445,975 shares worth $41.2M. The largest sale was Ultragenyx Pharmaceutical, an estimated $63.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

  • Baker Bros. Advisors's largest Q1 2026 buy was Mirum Pharmaceuticals: 445,975 shares worth $41.2M.
  • Baker Bros. Advisors added most to Praxis Precision Medicines in Q1 2026, an estimated $194M increase.
  • Baker Bros. Advisors's biggest Q1 2026 reduction was Immunocore, cutting an estimated $51.4M.
  • Baker Bros. Advisors fully exited Ultragenyx Pharmaceutical in Q1 2026, selling an estimated $63.8M.
  • Baker Bros. Advisors's ten largest holdings make up 73% of its $17.4B portfolio in Q1 2026.
  • Baker Bros. Advisors opened 8 new positions and closed 9 in Q1 2026.
  • Baker Bros. Advisors's portfolio value rose 2% quarter-over-quarter to $17.4B.

Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.